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Abstract
Background: The Netherlands Donor Feces Bank provides standardized ready-to-use donor faecal suspensions for
faecal microbiota transplantation treatment of patients with recurrent Clostridioides difficile infection.
Objective: The purpose of this study was evaluation of safety, feasibility and outcome of faecal microbiota trans-
plantation facilitated by a national stool bank.
Methods: The methods used included: observational cohort study of donors and recipients of faecal suspensions;
assessment of donor screening and patient selection performed by an expert panel of medical microbiologists,
gastroenterologists and infectious disease specialists; and patient outcome evaluated at different timepoints after
faecal microbiota transplantation.
Results: Of 871 volunteers who registered as a potential faeces donor, 16 (2%) became active donors. Nine donors
stopped or were excluded after a mean donation period of 5.7 months. In 2016–2019, 47 (27%) of 176 requests for
faecal microbiota transplantations were deemed not indicated by the expert panel. In total, 129 patients with
recurrent C. difficile infection were treated with 143 faecal suspensions in 40 different hospitals. The cure rate at two
months after a single infusion was 89% (107/120). Of 84 patients, long-term follow-up (median 42 weeks) was
available and sustained cure was achieved in 61 (73%). Early C. difficile infection relapses (within two months after
faecal microbiota transplantation) and late recurrences (after more than two months) occurred more frequently in
patients who received non-C. difficile antibiotics within three weeks after faecal microbiota transplantation and
in moderately to severely immunocompromised patients. Of 21 patients with C. difficile infection after faecal
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microbiota transplantation, 14 were cured with anti-C. difficile antibiotics and seven with a second transplantation.
No faecal microbiota transplantation-related serious adverse events were observed, but gastro-intestinal com-
plaints (nausea, abdominal pain or diarrhoea) persisted in 32% of the treated patients at long-term follow-up.
Conclusion: Faecal suspensions provided by a centralized stool bank, supported by a multidisciplinary expert
team, resulted in effective, appropriate and safe application of faecal microbiota transplantation for recurrent
C. difficile infection.
Level of evidence: Level II, prospective cohort study
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Faecal microbiota transplantation, Clostridioides difficile, stool bank, donor, cure rate, microbiome, microbiota
modifying therapy
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Key Summary
Established knowledge on this subject
• Faecal microbiota transplantation (FMT) is an established therapy for multiple recurrent Clostridioides
difficile infection (rCDI).
• Only a small percentage of potential donors are eligible after careful selection and screening.
• Centralized stool banks provide an opportunity for quality improvement of FMT.
Significant and/or new findings of this study?
• FMT that is facilitated by a national stool bank, is efficacious, safe and appropriately used.
• Consultation by a multidisciplinary FMT-expert team results in appropriate use of FMT.
• Post-FMT Clostridioides difficile infection (CDI) relapse can be treated with antibiotics directed against
CDI, even if these were ineffective prior to FMT in those patients.
• Faecal suspensions for rCDI treatment can be stored at –80C for up to two years, without loss of effectiveness.
Introduction
Faecal microbiota transplantation (FMT) is a very
effective treatment for recurrent Clostridioides difficile
infection (rCDI). In recent years it has been imple-
mented worldwide as an effective rescue therapy with
cure rates of approximately 85%.1–4 Transplanting
faecal microbiota of a healthy donor with the aim of
restoring a patient’s perturbed microbiota also appears
promising for several other disorders, such as ulcerative
colitis and hepatic encephalopathy.5,6 Careful donor
screening is required, minimizing the risk of pathogen
transfer or an impaired microbiota composition poten-
tially predisposing for disease. With the emergence of
FMT as a new treatment approach, stool banks are
needed to provide ready-to-use donor faecal suspen-
sions that are produced in a standardized way.7
Significant advantages of centralized donor screening
and production of donor faecal suspensions are the
possibilities of providing quality assurance, and
appropriate monitoring of potential yet unknown
adverse events.7
At present, stool banks operating at an institutional
level exists in several countries, and national operating
stool banks are active in the USA, the Netherlands and
England.8–12 In 2015, the Netherlands Donor Feces
Bank (NDFB) was founded as a non-profit national
stool bank. In addition to providing faecal suspensions,
the NDFB provides advice on the diagnosis, treatment
and follow-up of recurrent or severe Clostridioides dif-
ficile infection (CDI) by an FMT-expert panel of med-
ical microbiologists, gastroenterologists and infectious
disease specialists. The NDFB expert panel evaluates
each request for FMT.10
The aim of the current evaluation report was to
describe the results of donor screening and the outcome
of FMT performed for rCDI facilitated by the NDFB,
and under guidance of its expert panel. In addition,
donor-, patient- and faecal suspension-specific factors
underlying FMT treatment failure are addressed.
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Material and methods
Study design
This was a prospective, observational cohort study
describing the results of faeces donor screening and
patient outcome after FMT from the first performed
donor screening in January 2016, and FMT in May
2016, until August 2019.
Screening and selection of donors
The NDFB recruits healthy, unrelated volunteers who
can supply stool to the to the microbiology laboratory
within two hours after defaecation. The procedure of
donor recruitment, screening by questionnaire, interview
and laboratory testing was described before,10 and is
summarized in Supplementary Material Table S1.
Processing and storage of faecal suspensions
The NDFB uses standardized procedures for collec-
tion, preparation and storage of donor faecal suspen-
sions.10 In short, 60 g of donor faeces is used for the
preparation of one faecal suspension. Storage at –80C
is accommodated by a certified biobanking facility. At
the NDFB, the maximum shelf-life has been (arbitrari-
ly) determined as two years.
FMT consultation and treatment
Requests for faecal suspensions are submitted to the
NDFB by treating physicians using a standardized
form (www.ndfb.nl). The request is evaluated by at
least three medical specialists (a gastroenterologist,
medical microbiologist and infectious disease specialist)
of the NDFB expert panel. The indication for FMT is
assessed, the diagnosis of rCDI is verified, and the fea-
sibility and safety of FMT for the individual patient is
considered. Patients with at least two recurrent CDI
episodes or severe and therapy refractory CDI are eli-
gible. CDI is defined as diarrhoea (3 unformed stools
per 24 h for two consecutive days; or 8 unformed
stools per 48 h), in combination with a positive diag-
nostic test for C. difficile and absence of another more
likely cause of diarrhoea. To differentiate between
infection and asymptomatic colonization, a two-stage
testing algorithm is recommended.13 In particular,
presence of free C. difficile toxins is a prerequisite for
patients with gastro-intestinal comorbidity. Severe CDI
is defined by the presence of severe colitis or a compli-
cated course, with systemic toxin effects and shock that
may result in ICU admission or colectomy.14
If a patient is eligible for FMT, a donor faecal sus-
pension is transported to the requesting hospital on dry
ice and thawed according precise instructions.10
In general, prior to FMT, patients receive vancomycin
(125–250 mg four times a day) for a minimum of 4 days
until 24 h pre-FMT. For duodenal delivery, 2l of
KleanPrep (bowel lavage) is prescribed 1 day prior
to FMT.10 Treating physicians are instructed how to
perform FMT. The thawed faecal suspension is
infused through a duodenal tube, at an advised rate
of 10 cc/min. If FMT through a duodenal tube is con-
sidered unsafe or contra-indicated (i.e. due to a ham-
pered bowel passage or increased aspiration risk),
infusion via colonoscopy is advised. After infusion of
the donor faeces, patients are monitored for 2 h.1,10
Antibiotic stewardship to protect the microbiota post-
FMT is advocated to prevent a relapse of CDI
after FMT.10,15,16
Follow-up
At each FMT treatment, the patient and treating phy-
sician receive information on potential adverse events
and are advised to contact the NDFB if such an event
occurs. Treating physicians are advised to plan a rou-
tine follow-up visit at 3 weeks post-FMT and patients
are requested to complete a questionnaire. Patients
are routinely approached by an NDFB employee by
telephone 2 months after FMT, and for the present
evaluation report also at a later time-point between
January 2019–August 2019 (19–143 weeks) post-FMT
for long-term follow-up. Information about recurrence,
hospital admission, possible FMT-related adverse
events and antibiotic use is collected. We defined
early relapse as a CDI episode within two months fol-
lowing FMT,14 whereas a CDI episode after two
months post-FMT was regarded as late recurrence.
We defined cure as resolution of all CDI symptoms,
and no CDI relapse within three weeks (primary
cure), two months (cure at two months) or long-term
follow-up (sustained cure). We categorized the relation-
ship between adverse events and FMT as follows: def-
initely related, probably related, possibly related and
unrelated to FMT.17
Statistical analysis
The statistical analysis was performed using SPSS 23.0
statistical software. Continuous data are presented as
mean (range), or median in the case of a skewed distri-
bution. Possible associations between FMT treatment
outcome and patient, faecal suspension or donor char-
acteristics were tested by a Pearson’s Chi-squared test
or Fisher’s exact test, where appropriate. An odds
ratio was calculated using logistic regression and pre-
sented with a 95% confidence interval (95% CI).
For ordinal data, a linear-by-linear association test
was used. Kaplan-Meier curves and log-rank tests
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were performed to assess CDI-free survival. A two-
tailed significance level of p<0.05 was considered
statistically significant. Missing data and patients lost-
to follow-up were mentioned but data was not cor-
rected for this.
Results
Donor selection and screening
Since the initiation of the NDFB, 871 volunteers regis-
tered as potential faeces donors. After receiving infor-
mation about donor requirements, 603 withdrew and
268 completed an online questionnaire (Table 1). Based
on the questionnaire, 83 (31%) donors were invited
for an interview, followed by microbiological testing.
After evaluation of the interviews, screening and rescre-
ening of faeces and serum, only 16 volunteers were eli-
gible as faeces donors, which is 6% of volunteers
completing the questionnaire and 2% of all
initially interested individuals (Table 1). Of these
16 active donors, 10 (63%) were female, the mean
age was 33 (range 24–57) years, and the mean body
mass index (BMI) was 22.4 (range 19.6–24.8) kg/m2.
Asymptomatic, transient carriage of potential
pathogens was occasionally found at re-screening
Table 1. Results of the donor selection and screening process.
Donors (%) Action Excluded (%) Exclusion reasonsa
871 Request for more infor-
mation by donor
603 (69%) 52% (n¼ 311) withdrawal after reading additional infor-
mation, 22% (n¼ 132) unable to deliver faeces 2
h after defaecation, 20% (n¼ 121) age >50 years,b 8%
(n¼ 49) increased risk disturbed microbiota (bowel
complains, medication use, comorbidity, depression,







185 (69%) 22% (n¼ 41) comorbidity/medication use, 22% (n¼ 40)
BMI<18.5 or >25 m2/kg, 18% (n¼ 33) (history of)
depression, 15% (n¼ 28) profession of healthcare
worker,c 14% (n¼ 25) age >50 years,b 14% (n¼ 25)
bowel complaints, 12% (n¼ 22) inability to deliver
faeces <2 h, 10% (n¼ 19) withdrawal after completing
questionnaire, 6% (n¼ 12) (close relative with) IBD, 5%
(n¼ 9) frequent travelling, 4% (n¼ 7) risk factor for
colon carcinoma,d 3% (n¼ 6) high risk sexual behav-




Interview 17 (20%) 65% (n¼ 11) donors withdrawal or failure to deliver
faeces <2 h once a week, 35% (n¼ 6) donors excluded
based on interview (IBS complaints, comorbidity, psy-




Faecese screening 47 (71%) 89% (n¼ 42) Dientamoeba fragilis, 15% (n¼ 7) MDRO, 9%
(n¼ 4) Blastocystis sp., 4% (n¼ 2) Helicobacter pylori,














6 (27%) Exclusion of quarantined donor suspensions: 83% (n¼ 5)
difficulty to implement donation in daily practice, 17%
(n¼ 1) MDRO and refusal to perform rescreening
BMI: body mass index; IBS: irritable bowel syndrome; MDRO: multidrug-resistant organism.
aSome volunteers had multiple exclusion criteria, exclusion is displayed as the percentage of total excluded donors as result of a particular
screening step.
bFrom September 2018 changed to 55 years, or 60 years with negative colon carcinoma screening.
cHigher risk of temporary carriership of pathogens.
dClose relative with colon carcinoma with an onset below the age of 50 years.
eScreening algorithm used: first screening includes: Dientamoeba fragilis, microscopy for Blastocystis sp., MDRO and Helicobacter pylori screening,
if negative, then additional tests are performed (Supplementary Material Table S1).
fThree donors were excluded at first screening, successfully decolonized of MDRO, D. fragilis or E. histolytica, and they subsequently continued the
donor screening program.
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(multidrug-resistant organism (MDRO): n¼ 4, norovi-
rus: n¼ 2, rotavirus: n¼ 1, sapovirus: n¼ 1, parechovi-
rus: n¼ 1, Salmonella species: n¼ 1, or Dientamoeba
fragilis: n¼ 1). Nearly all active donors experienced
one or more transient episodes with upper respiratory
complaints, diarrhoea, temporary change of defaeca-
tion pattern or antibiotic use, for which donations
were temporarily stopped. Nine of the 16 (56%)
donors stopped or were excluded after a mean period
of 5.7 months (range 1–14 months). Reasons for dis-
continuation were persistent carriage of potential
pathogens during repeated testing (Blastocystis species:
n¼ 2, MDRO: n¼ 1, or D. fragilis n¼ 1) or a too heavy
burden of required time and logistics (n¼ 5).
FMT consultation
Since May 2016, 176 FMT requests for treatment of
rCDI or therapy refractory CDI patients were reviewed
by the expert panel. Of these requests, 47 (27%) were
deemed not indicated. The most frequent reason for
rejection was C. difficile carriership in combination
with diarrhoea due to inflammatory bowel disease
(IBD) or another, unknown cause. Detailed results of
the evaluation of FMT requests are listed in Table 2.
FMT treatment
In total, 129 patients with CDI were treated with 143
FMTs in 40 different hospitals throughout the
Netherlands. Suspensions obtained from 12 of the 16
approved donors were used. The mean age of the
patients was 69.9 years (range 2–96), and 60% were
female. Patients suffered from a mean of 4.2 (range
1–10) CDI episodes before FMT was considered.
Most patients had rCDI (Table 2). Four patients
received an FMT for a first episode of severe,
therapy-refractory CDI, of whom one received multiple
FMTs (six in total). The majority of FMTs (127/143,
89%) were infused through a duodenal tube. FMT via
the lower gastro-intestinal route was performed by
colonoscopy because of motility disorders (n¼ 4), an
already planned colonoscopy to rule out IBD (n¼ 8);
or sigmoidoscopy because of an ileus due to severe CDI
(n¼ 4).
Outcome of FMT treatment
Follow-up data were available for 128 of 129 patients
at three weeks, and 120 patients at 2 months after
FMT. Three patients (2%) died within 3 weeks due
to causes unrelated to the FMT. The primary cure
rate at 3 weeks after a single FMT infusion was 91%
(117/128). Cure at 2 months post-FMT was 89% (107/
120). Thirteen patients suffered from an early relapse at
a median of 1 week (range 0–5 weeks) post-FMT. Of
the 129 FMT-treated patients; 11 (9%) were deceased
by the time of long-term follow-up, 34 (26%) were lost
to follow-up. From 84 (65%) patients, long-term
follow-up was available with a median of 42 weeks
Table 2. Results of the evaluation of faecal microbiota transplantation (FMT) requests by multidisciplinary FMT expert panel.
FMT decision Number of requests
FMT request rejected by NDFB expert panel 47/176 (27%)
Reasons of rejection of the 47 FMT requests:
C. difficile carriership and diarrhoea due to other cause; 30 (64%)
 Diarrhoea with unknown cause –18
 Diarrhoea due to IBD –12
Anti-CDI antibiotics advised instead of FMT; 11 (23%)
 First, mild recurrence –7
 New CDI infection (too long interval between CDI episodes) –4
Long-term antibiotic use/elective operation 3 (6%)
Withdrawal of FMT request after observed antibiotic treatment effect,
by treating physician or patient
3 (6%)
Request for FMT approved by NDFB expert panel 129/176 (73%)
FMT indicationa
 Multiple recurrent CDI 125 (97%)
 Severe, therapy refractory CDI 3 (2%)
 Refractory CDI 1 (1%)
CDI: Clostridioides difficile infection; IBD: inflammatory bowel disease.
aOne hundred and forty-three FMTs performed in 129 patients. Ten patients received multiple FMTs; nine patients for treatment of a post-FMT
CDI relapse (seven patients cured with a single repeat FMT, one patient cured with two repeat FMTs, one patient cured with antibiotics after a
repeat FMT) and one patient received sequential FMT treatment for severe, therapy refractory CDI (in total six FMTs; three FMTs for a first episode
and three FMTs for the relapse).
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(range 19–143 weeks, interquartile range 26–97 weeks).
Ten patients developed a late CDI recurrence after a
median of 17 weeks (9–57 weeks) post-FMT. Thus,
sustained cure was achieved in 61 of 84 (73%) patients
still alive at long-term follow-up. Figure 1 shows the
CDI-free survival over time. The 23 patients suffering
from post-FMT CDI had symptoms of diarrhoea,
either in combination with a positive toxin enzyme
immuno assay (EIA) (14/23, 61%), polymerase chain
reaction (PCR) (5/23, 22%), or were diagnosed with
unclear methods but with clinical response to vanco-
mycin treatment (4/23, 18%). Most patients experienc-
ing CDI post-FMT eventually successfully cured (21/
23), either by antibiotics alone (14/21, 67%; received
fidaxomicin, four vancomycin, one metronidazole and
one fidaxomicin) or by a second FMT (7/21, 33%; of
whom one patient needed a third FMT). In two
patients CDI treatment was not initiated, the patients
died of an underlying disease with concurrent develop-
ment of CDI.
Risk factors for post-FMT CDI
Patients with an early CDI relapse post-FMT had more
often received non-CDI antibiotics during the first 3
weeks after FMT compared to patients without relapse
(39% versus 15%) (Table 3). Antibiotic use preceded a
late CDI recurrence in 80% of patients. Nonetheless,
antibiotic use shortly after FMT was still a significant
predictor of all CDI episodes post-FMT (both early
AND late) (40% (8/20) compared to 15% (14/95),
p-value 0.001, Supplementary Material Figure S1). In
addition, early CDI relapses were observed more fre-
quently in patients who were moderately (3/23) to
severely (2/3) immunocompromised (Table 3). A
trend was observed towards more CDI (early relapse
or late recurrence) post-FMT in immunocompromised
(31%, 8/26) versus immunocompetent patients (15%,
15/101) (p-value 0.054, Supplementary Material Figure
S2). No other patient or faecal suspension characteris-
tic significantly differed between those who relapsed
and those cured (Table 3). Importantly, a longer proc-
essing time of faecal suspensions (mean 168 min, range
65–355 min) or longer storage time at –80C (mean 269
days, range 34–730 days, 30/129 were stored >1 year)
did not negatively influence the success rate of FMT.
Donor selection did not influence the outcome of FMT;
no differences between donors could be detected (p-
value 0.10, individual donor data in Supplementary
Material Table S2).
Patients: follow-up of adverse events
On the day of FMT, 66% (62/94) of patients had mild,
transient gastro-intestinal complaints (Table 4). At 3
weeks and at long-term follow-up, a subset of patients
still reported abdominal pain (both 21%) and diar-
rhoea (27% and 33%, respectively). The self-rated
defaecation pattern after FMT compared to the pre-
existent defaecation pattern (before the CDI episodes)
had improved in 16% at 3 weeks, and in 38% at long-
term follow-up (Table 4).
No definitely or probably related serious adverse
events were reported. Five (5/128, 4%) FMT (proce-
dure)-related adverse events were observed (Table 5).
Regurgitation of donor faeces occurred in four patients
shortly after duodenal infusion of the faecal suspension
(Table 5). During the first three weeks after FMT, 23%
(26/115) of the patients were admitted to the hospital
or had prolonged hospitalization, of which nine (8%)
for possibly FMT-related indications (Table 5). The
most frequently observed infections after FMT were
urinary tract infection (UTI) (8%, 9/115) or pneumo-
nia (5%, 6/115). The majority of patients suffering of
these infections had known predisposing factors for
UTI or pneumonia (Table 5).
Discussion
During the 4 years since its establishment, the NDFB
has evaluated over 175 FMT requests and provided
standardized FMT to almost 130 patients affected by
rCDI. A high cure rate of nearly 90% at 2 months after


















































Follow-up time in weeks
Clostridiodes difficile infection-free survival
CDI event Deceased or lost-to follow-up
Figure 1. Kaplan-Meier curve of the Clostridioides difficile
infection (CDI) (faecal microbiota transplantation (FMT) fail-
ure, early relapse or late recurrence)-free survival post-FMT.
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The cure rate of FMT facilitated by the NDFB
appears high compared to the 76% cure rate reported
in a recent meta-analysis of single FMTs for rCDI.4
This may be explained by the stringent criteria for diag-
nosis and treatment applied by our FMT expert
panel.13 This expert panel discusses the indication for
FMT and provides advice during treatment and follow-
up of the patients. We rejected a quarter of FMT
requests, mainly because the diarrhoea was attributed
to another cause that coincided with C. difficile carrier-
ship. Thus, consultation might prevent inappropriate
use of FMT and increases the clinical benefits and
cost-effectiveness. Our observation is similar to a pre-
vious report from an FMT-expert centre, which
showed that 25% of patients referred for FMT did
not have confirmed rCDI.18 In particular, new onset
or persistent activity of IBD appears to be a diagnostic
pitfall.18,19 In addition, non-responsiveness to anti-CDI
Table 3. Patient, donor and faecal suspension risk factors for Clostridioides difficile infection (CDI) relapse within two months










(OR (95% CI), p-value)
Patient sex (female) 77% (10/13) 58% (67/116) OR 2.4 (0.6–9.3), p-value 0.24
Donor sex (female) 54% (7/13) 50% (58/116) OR 1.2 (0.4–3.7), p-value 0.79
Donor – patient sex mismatch 39% (5/13) 47% (54/116) OR 0.7 (0.2–2.3), p-value 0.58
Patient’s age (at FMT) 69 years (41–96) 70 years (2–92) p-value 0.76
Donor’s age (at donation) 36 years (24–46) 35 years (24–46) p-value 0.82
Lower gastro-intestinal infusion of FMT
(sigmo- or colonoscopy)
23% (3/13) 8% (9/116) OR 3.6 (0.8–15.3), p-value 0.10
Mean processing time of the faecal sus-
pension (defaecation to freezer)
163 min 168 min p-value 0.73
Mean storage time of the faecal suspen-
sion (at –80C)
214 days 275 days p-value 0.27
Severe CDI as indication for FMT 8% (1/13) 2% (2/116) OR 4.8 (0.4–56.3), p-value 0.28
Prior CDI relapses, before FMT is
performed
2.6 (13) 2.8 (114) p-value 0.69
PPI use 61% (8/13) 51% (55/108) OR 1.5 (0.5–5.0), p-value 0.47
Comorbidity of IBD 8% (1/13) 11% (13/114) OR 0.7 (0.1–5.4), p-value 1.0
Severe kidney comorbidity: dialysis or
kidney transplantation
8% (1/13) 9% (24/112) OR 1.0 (0.1–8.2), p-value 1.0
rUTI in medical history 0% (0/13) 8% (9/113) p-value 0.60a
Use of non-CDI antibiotics in between the
prior CDI episodes
46% (6/13) 38% (43/113) OR 1.4 (0.4–4.4), p-value 0.57
Immunocompromiseda
– Not 61% (8/13) 82% (93/114) p-value 0.01
– Moderate 23% (3/13) 18% (20/114)
– Severe 15% (2/13) 1% (1/114)
Hypervirulent cladeb 25% (2/8) 20% (13/65) OR 1.3 (0.2–7.4), p-value 0.66
Post-FMT hospitalization for non-CDI
indications post-FMTc
23% (3/13) 14% (14/102) OR 1.9 (0.5–7.7), p-value 0.41
Post-FMT infection (other than CDI)c 15% (2/13) 17% (17/102) OR 0.9 (0.2–4.5), p-value 1.00
Post-FMT antibiotic use (non-CDI
indications)c
39% (5/13) 15% (15/102) OR 3.6 (1.0–12.6), p-value 0.03
CI: confidence interval; IBD: inflammatory bowel disease; OR: odds ratio; PPI: proton pump inhibitor; rCDI: recurrent Clostridioides difficile
infection; rUTI: recurrent urinary tract infection.
Percentages and final odds ratio with 95% CIs of FMT-treated patients with or without early CDI relapse.
aImmunocompromised classified as: not, moderate or severe. Patients are regarded as severely immunocompromised when: neutropenic,
(scheduled or received last 100 days) an allogenic stem cell transplantation, active Graft-versus-host-disease requiring immunosuppressive
agents, and moderately immunocompromised when: having<200 CD4 T-cells/ml, prolonged use of corticosteroids at a mean dose of 0.3 mg/kg/d
of prednisone equivalent for >3 weeks, treatment with other recognized T-cell immunosuppressants during the last 90 days or have an inherited
severe immunodeficiency.
bHypervirulent clade RT027 (016, 019, 0247, 036, 075, 111, 112, 153, 156, 176, 208, 273) and clade RT078 (033, 045, 066, 078, 126, 127).
cIn the first 3 weeks post-FMT.
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Table 4. Gastro-intestinal complaints post-faecal microbiota transplantation (FMT).
Gastro-intestinal complaint Day of FMTa 1-week post-FMTa 3-weeks post-FMTa LTFUb
Nausea (% yes) 20% (19/94) 14% (13/96) 11% (11/97) 18% (13/73)
Abdominal pain (% yes) 33% (31/93) 28% (27/97) 21% (21/98) 21% (15/71)
Diarrhoea (% yes) 52% (48/93) 30% (29/97) 27% (26/97) 33% (24/73)
Self-rated defaecation pattern (post-FMT
vs before CDI episode)
n/a n/a
 Improved 16% (13/80) 38% (25/65)
 Similar 68% (54/80) 46% (30/65)
 Deteriorated 16% (13/80) 15% (10/65)
LTFU: long-term follow-up; rCDI: recurrent Clostridioides difficile infection.
aA questionnaire is filled in by the patient or treating physician at regular follow-up 3–4 weeks post-FMT.
bLTFU: median 42 weeks, range 19–143 weeks.
Table 5. (Serious) adverse events (AEs) within three weeks after faecal microbiota transplantation (FMT).
Description adverse event Number of patients
Definitively or probably related to FMT
SAE None 0% (0/128)
AE Procedure-related AEs
– Regurgitation, no aspiration, patient successfully treated




Possibly related to FMT
SAE Hospitalization within 3 weeks post-FMT due to:
– Lower respiratory tract infection (causing pathogen unknown)a






AE Gastro-intestinal (see Table 4)
Infections
– Urinary tract infection (causing pathogen unknown)b
– Urinary and lower respiratory tract infectiona
Other
– Fever







SAE Hospitalization (or prolonged hospitalization) within 3 weeks post-FMT
– Lower respiratory tract infection (COPD exacerbation due to Moraxella catarrhalis
and RSV infection)
– CDI relapse
– Related to pre-existent comorbidity (elective surgery dialysis shunt, complications
knee prosthesis, perforated diverticulitis, hyponatraemia with tongue carcinoma,
GvHD after allogenic stem cell transplantation (already existing), diarrhoea due to
chemotherapy)
– Death within 3 weeks post-FMT due to comorbidity (tongue carcinoma/hypona-
traemia, sepsis due to pneumonia, comorbidity GvHD lung after allo-SCT)
– Infection with Yersinia pseudotuberculosis post-FMT, donor suspension tested
negative (with both PCR and culture (cold enrichment-broth)












– Otitis, infection of toe, phlegmon groin
- 3
CDI: Clostridioides difficile infection; SAE: serious adverse event; UTI: urinary tract infection; COPD: chronic obstructive pulmonary disease; CVA:
cerebro vascular accident; GI: gastrointestinal; GvHD: graft versus host disease; PCR: polymerase chain reaction; RSV: respiratory syncytial virus;
SCT: stem cell transplantation.
aFour patients (80%, 4/5) developing a pneumonia had a medical history of either chronic obstructive pulmonary disease, asthma or lung
fibrosis.
bFour patients (44%, 4/9) had known predisposing factors for UTI (medical history of pyelonephritis, diabetes type II and benign prostate
hypertrophy, Sachse urethrotomy or Bricker bladder).
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antibiotics seems to point to an alternative diagnosis
rather than therapy-refractory CDI in most patients. In
fact, only four of our 129 patients were deemed to
suffer from therapy-refractory CDI by the expert-
panel.
A subgroup of rCDI patients remains vulnerable for
CDI after FMT, as 9% (10/107) of initially cured
patients developed a late CDI recurrence. Of this
group, 80% had used antibiotics preceding the recur-
rence, in contrast to only 39% of patients with an early
relapse. This indicates that antibiotic use after FMT
should be limited as much as possible for a prolonged
period. It also emphasizes that a long follow-up after
FMT is mandatory to assess the long-term efficacy of
FMT. The majority (61%) of early relapses were not
preceded by antibiotics, indicating that other factors
also contribute to FMT failures, such as an immuno-
competence. Other studies have identified Charlson
Comorbidity Index,20 the severity of CDI,21,22 previous
(CDI) hospitalisation,22,23 inpatient status,22 surgery,23
female sex23 and older age24 to predict recurrence after
FMT. We did not recognize donor-related factors con-
tributing to FMT outcome, confirming previous
reports.25–27 The majority of patients with post-FMT
CDI were cured with antibiotic treatment, suggesting
that this should be considered a different entity com-
pared to the antibiotic resistant episodes prior to FMT.
This could be explained as an FMT-mediated gut
microbiota reset, which renders patient less susceptible
to rCDI after treatment with antibiotics alone.
In our experience, duodenal delivery of donor faeces
was highly effective and certainly not inferior to deliv-
ery by colonoscopy, although this report was not
designed as a study to compare routes of delivery.
Duodenal FMT has a small risk of regurgitation. To
prevent this, we currently advise slow infusion of the
faecal suspension in the duodenum (10 cc/min), room
temperature of the suspension to avoid cold shock, and
colonoscopic delivery in case of possible bowel dysmo-
tility. After introduction of these precautions, regurgi-
tation was no longer recognized. We did not observe
FMT-related serious adverse events. Several patients
developed a UTI (9/115) or pneumonia (6/115) after
FMT. This might be explained by existing predisposing
factors in most patients, although a relationship
with FMT cannot be fully excluded. Interestingly, it
has been suggested that the incidence of UTI could
decline after FMT due to a reduced abundance of
Enterobacterales in the gut.28 About 21–33%
of patients suffered from abdominal complaints at
follow-up. This is in line with a previous report, in
which no FMT-attributable factors could be identi-
fied.29 Remarkably, at long-term follow-up, the self-
rated defaecation pattern improved (38%), or had
stayed unchanged (46%) in most of our patients,
compared to the period before the first CDI episode,
suggesting that gastro-intestinal symptoms after FMT
could be related to post-infectious complaints and pre-
existent comorbidity. Post-infectious irritable bowel
complaints after CDI were also reported in 4–25% of
patients not given FMT.30
We observed a low 2 months mortality rate of 3%
(3/120) after FMT, which is lower than the 30-day mor-
tality rate of primary CDI in the Netherlands31 (9%
overall mortality). The mortality of 12% at long-term
follow-up (median 42 weeks) is lower than observed in
two other FMT cohorts (20% at weeks 30 and 48 post-
FMT).32,33
A strength of our evaluation report is the structural
follow-up of donors and patients of a complete stool
bank cohort, with use of standardised questionnaires
and over a long period of time post-FMT. Several stud-
ies report on retrospective analyses of only specific
patient groups treated with stool bank FMT-
suspensions without structural long-term follow-up.
In one of the largest retrospective studies, 307 of
528 (39%) rCDI patients were successfully contacted,
a sustained cure of 76% at 34 months follow-up
was observed.33 Our high sustained cure rate confirms
this observation. A limitation of our report is that 26%
patients were lost to long-term follow-up, and late
recurrent CDI may be overestimated as these were
actively reported to the NDFB by the local physicians.
This is supported by the fact that no unreported recur-
rences were detected with the follow-up questionnaires.
Another limitation, also related to the setting of a
national stool bank, is the lack of nation-wide
uniform microbiological testing, which may have influ-
enced the process of consultation and the outcome of
the treatment.
The risk of infectious complications after FMT
depends on appropriate donor screening. This may
even be more important for severely immunocompro-
mised patients, as suggested by the cases where transfer
of MDRO by FMT in neutropenic patients resulted in
sepsis and death.34 Only 2% of potential donors were
eventually eligible after extensive selection and screen-
ing. This is comparable to the donor qualification rate
of 3% of a large US stool bank.35 Others reported
higher donor acceptance rates of 10–31%.36–38
Unfortunately, donor exclusion criteria and
screening-protocols are heterogeneous and often
incomplete,39 underlining the need for standardization
of donor screening. After initial donor acceptance, a
quarter of our donors were excluded at the first quar-
antine screening. In addition, over half of the active
donors stopped donating after six months for logistic
reasons or persistent colonization by a potential path-
ogen. A high dropout rate was also observed in
Canada; four of five approved donors were excluded
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during the quarantine period due to travel or acute
gastro-enteritis.40 This demonstrates the need for a
quarantine period and targeted screening on indication
before faecal suspensions can be used safely. Although
the identification of potential pathogens such as
MDRO, norovirus or rotavirus in asymptomatic
active donors is rare, the NDFB performs complete
microbiological screening of the dedicated faecal sus-
pension when the recipient is severely immunocompro-
mised. In the future, donor selection will be even more
challenging if specific donor characteristics are required
for FMT treatment for indications such as ulcerative
colitis or hepatic encephalopathy.25 In this regard, the
finding that faecal suspensions with a shelf-life of 2
years at –80C are safe and evenly efficacious for treat-
ment of rCDI is encouraging.
In conclusion, the use of strict donor selection crite-
ria, standardized processing and storage of FMT sus-
pensions, and consultation by a multidisciplinary
FMT-expert team, as provided by a professional
stool bank, results in safe and efficacious application
of FMT for rCDI. With the increasing number of
reports pointing to potential beneficial effects of
FMT in patients with a variety of gastro-intestinal
and extra-intestinal disorders, a growing demand of
FMT can be expected in the near future. Initially,
experimental studies will have to be performed in a
controlled setting. However, for routine clinical prac-
tice, standardised preparation, quality control and
careful and long-term monitoring of outcomes and
adverse events, stool banks are required. We encourage
FMT centres and stool banks to utilize a multidiscipli-
nary FMT team of experts to fill a currently existing
gap, and ensure a safe and controlled application
of FMT.
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